If we assume that PKC is a molecular target for ARC activity then this may explain the selective ability of ARC to kill cancer cells, since other PKC inhibitors have also been shown to have greater activity against cancer cells than their 'normal' counterparts [22]. Here, ARC is linked to cancer.